Emergent BioSolutions | Koszty Sprzedaży



Koszty Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 21.65M 913K 2025-09
Akebia Therapeutics USD 8.13M 2.41M 2025-03
ALKERMES USD 51.59M 2.13M 2025-09
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amarin USD 16.89M 18.51M 2025-03
ANI Pharmaceuticals USD 116.02M 18.12M 2025-09
BioMarin Pharmaceutical USD 144.93M 10M 2025-09
Coherus Biosciences USD 2.65M 31.2M 2025-03
Exact Sciences USD 266.81M 18.18M 2025-09
Exelixis USD 26.48M 7.91M 2025-12
Glaxosmithkline GBP 3.01B 853.01M 2025-09
Heron Therapeutics USD 9.46M 1.61M 2024-09
Ionis Pharmaceuticals USD 2.34M 1.81M 2025-09
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Lexicon Pharmaceuticals USD 17.81M 3.41M 2024-06
Lonza CHF 2.28B 189M 2025-06
Merck USD 3.32B 531M 2025-12
Moderna USD 207M 88M 2025-09
Myriad Genetics USD 61.9M 600K 2025-09
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Pacira USD 48.6M 6.59M 2025-09
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 23.32M 7.83M 2025-09
Sanofi EUR 4.29B 421M 2025-12
Sarepta Therapeutics USD 151.45M 1.77M 2025-09
United Therapeutics USD 100.9M 74.3M 2025-09
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Xoma 116K 112.7K 2024-06


Emergent BioSolutions Koszty Sprzedaży - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.